Targeting mtor-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses
2009
Targeting mTOR-Dependent Tumors with Specific Inhibitors
publication
Evidence: moderate
Author Information
Author(s): Furic L., Livingstone M., Dowling R.J.O., Sonenberg N.
Primary Institution: McGill University
Hypothesis
Can targeting the mTOR pathway with specific inhibitors improve cancer treatment outcomes?
Conclusion
Targeting the mTOR pathway may provide effective treatment options for certain cancers, particularly those with specific genetic mutations.
Supporting Evidence
- Clinical trials have shown that endometrial tumors with PTEN inactivation respond well to temsirolimus.
- Renal cell carcinoma has shown some sensitivity to mTOR inhibitors.
- Temsirolimus was approved for treating patients with renal carcinoma in May 2007.
Takeaway
Scientists are studying how to use special drugs to stop cancer cells from growing by targeting a specific pathway in the cells.
Methodology
This review summarizes existing knowledge on mTOR inhibitors and their clinical trials.
Limitations
Some cancers have not responded to mTOR inhibitors despite having mutations that should make them sensitive to treatment.
Want to read the original?
Access the complete publication on the publisher's website